+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07434791

Goal-Directed Strategic Approach Using New Therapies to Reduce Kidney and Cardiovascular Risks in Patients with Diabetic Kidney Disease

Led by Sunnybrook Health Sciences Centre · Updated on 2026-09-04

100

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the feasibility, safety, and implementation of an early goal-directed Cardio-Kidney-Metabolic CKM care strategy compared with usual care in adults living with type 2 diabetes and diabetic kidney disease who are at increased cardiovascular risk. This pilot randomized controlled trial aims to assess whether a structured approach integrating kidney, cardiovascular, and metabolic risk management can be safely and effectively implemented within routine nephrology practice, informing a future larger trial. Participants will be randomly assigned to one of two groups one receiving a nephrologist-led CKM care strategy involving risk assessments, shared decision-making, guideline-directed medical therapies including RASi, SGLT2i, nsMRA, and GLP-1 RA, and ongoing safety monitoring the other receiving standard nephrology care based on usual clinical practice and clinician judgment. The study follows participants for 12 months, monitoring treatment uptake, adherence, and safety outcomes. During the study, participants will have regular assessments to evaluate recruitment, retention, treatment implementation, and safety. Researchers will collect data on medication adherence, cardiovascular and kidney-related health measures such as blood pressure, urine albumin-to-creatinine ratio, and estimated glomerular filtration rate, hospitalizations, and mortality. This comprehensive follow-up aims to inform the design of a future definitive trial, with total participation lasting about one year.

CONDITIONS

Brief Title

Goal-Directed Therapy to Reduce Kidney and Cardiovascular Risk in Diabetic Kidney Disease (GOLD-STANDARD)

Research Team

A

Ayodele Odutayo, Doctor

G

GOLD STANDARD Coordinating Centre

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here